Background Synbiotics (combination of prebiotics and probiotics) may serve as a supportive dietary supplement-based strategy aft er colectomy for cancer. Th e potential benefi ts of early postoperative administration of synbiotics on the gastrointestinal function-related quality of life inpatients were explored.
Introduction
Th e unavoidable anatomical distortion of bowel anatomy due to surgical resections for colorectal cancer (CRC) may lead to intestinal functional disturbances [1] . Preoperative preparation strategies, such as mechanical bowel preparation may disturb the well-established functional balances between enteric fl ora and normal large bowel function [2] . Bowel disorders may directly or indirectly aff ect health-related quality of life (HRQoL) and this may be refl ected to proportional alterations in the scoring of standardized measurement tools, such as HRQoL questionnaires [3] [4] [5] [6] [7] . A validated instrument that assesses gastrointestinal function is the Gastro-Intestinal Quality Life Index (GIQLI) [3] [4] [5] . GIQLI may off er valuable insight in rating postoperative gastrointestinal function status at CRC patients. Th e 30-item questionnaire (QLQ-C30) of the European Organization for Research and Treatment of Cancer (EORTC) has already widely assessed CRC patients' HRQoL and it includes items on gastrointestinal function, such as the symptom domains "diarrhea" and "constipation" [4, 6, 7] . HRQoL instruments may off er "functional surveillance" by monitoring, ranking and quantifying the "subjective" patient's symptoms.
Initial HRQoL postoperative deterioration and postcolectomy gastrointestinal disturbances are expected to be temporary enduring 3-6 months [7] . Interventional strategies and enhancing therapeutic regimens at the immediate postoperative period may have a soothing eff ect on patients' symptoms. Probiotics are cultures of live microorganisms that might benefi cially aff ect the host by improving the composition and the equilibrium of indigenous microfl ora [8] . Prebiotics are nondigestible ingredients (fi bers) that reach the colon and serve as substrate for fermentation by probiotics and indigenous colonic bacteria to nutrients benefi cially improving host health [9] . Synbiotics are the combination of probiotics and prebiotics and are believed to be more effi cient in terms of gut health and function [10] . Administration of proand/or synbiotics may serve as one of the supportive modulating dietary supplement-based strategies in CRC patients [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] .
Studies reporting on the eff ects of pro-/synbiotics on functional outcome, gastrointestinal symptoms and HRQoL aft er CRC surgery are rather scarce [14, 22, 25] . In an eff ort to clarify the eff ects of early postoperative administration of synbiotics on bowel functional outcome, as this is measured by gastrointestinal-oriented HRQoL instruments and domains, we prospectively carried out a randomized trial in a selected cohort of patients undergoing colorectal resection for cancer. Th is study aimed to justify the early postoperative use of oral synbiotics for the minimization of the adverse eff ect of surgery on the short-and mid-term gastrointestinal symptomsassociated HRQoL.
Patients and methods

Study design
Th is was a prospective, double-blind, randomized controltrial (RCT) of two groups. Th e study was carried out in the First Department of Propaedeutic Surgery of Athens Medical School at Hippocration Hospital, Athens, Greece.
Participants
Patients eligible for inclusion were those with histological documentation of cancer of the colon or rectum, operated between July 2008 and April 2012. Patients of both genders, aged between 18 and 80 years,who were candidates for elective colorectal resection for cancer were included in the study. Patients were excluded if they: denied written informed consent; were pregnant; had hereditary cancer; had a history of infl ammatory bowel disease; had metastatic disease at presentation; required permanent or temporary stoma; had emergency operation; had major postoperative complications; had disease progression during the study period; or did not tolerate liquid diet by the 5 th postoperative day (POD).
Study intervention
Randomization and method of allocation concealment
Th e study patients were randomized before surgery to receive either synbiotics (Synbiotics group) or placebo (Control group). Equal randomization was accomplished using a computer-generated random allocation schedule. Th e method of allocation concealment was sequentially numbered sealed opaque envelopes technique. Both synbiotics and placebo preparations were in foil-sealed sachets stored in identical numbered containers. Both study products were white powders, identical in weight, smell, and taste. Th us, the identity of the specifi c product was blind to participants, support staff and investigators for the entire duration of the study period.
During the study period, of the 75 patients who initially consented to participate, 38 in the Synbiotics group and 37 patients in the Control group completed the entire trial (Fig. 1) .
Arms assigned interventions and study medications
A specifi c multistrain/multifi ber synbiotic composition of prebiotics and probiotics (Synbiotic Forte™, "IONIA" Pharmaceuticals, Athens, Greece) was administered at the active comparator arm of the study. It contained 10 [11] of each of four lactic acid bacteria (LAB): Pediococcus pentosaceus 5-33:3, Leuconostoc mesenteroides 32-77:1, Lactobacillus paracasei ssp. paracasei 19, and Lactobacillus plantarum 2362, and 2.5 g of each of the four fermentable fi bers (prebiotics): b-glucan, inulin, pectin and resistant starch. Th e synbiotics were delivered in sachets and then mixed with water (12 g in 250 mL of water once daily). Th e treatment started on the day patients tolerated per os liquid intake (2 nd -4 th POD). Th e intervention period lasted 15 days. Th e patients belonging to the placebo comparator arm received only the 4 fi bers and no LAB (12 g in 250 mL of water once daily for 15 days). All the subjects were interviewed by a dedicated research fellow (KP) and reactions to the product, and any adverse events occurring in the 15-day period were recorded. During the study period, no parenteral or enteral nutritional supplementation was given. All patients received a regular diet preoperatively, and a low-residue diet 1 day before surgery. For mechanical bowel preparation the aft ernoon before the operation all patients were given 45 mL of regimen containing monobasic sodium phosphate monohydrate and dibasic sodium phosphate heptahydrate and the dose was repeated 4-6 h later. For chemoprophylaxis, 500 mg of metronidazole and 1 g of cefoxitin were given prior to anesthesia and continued for 24 h aft er the operation. During the postoperative period, all patients received the regular parenteral hydration infusion.
Outcome measures and questionnaires
Th e primary end point of the study was the assessment of gastrointestinal function-related quality of life at 1, 3 and 6 months postoperatively by the use of the validated questionnaire GIQLI. Secondary endpoint was the assessment of functional bowel disorders ("diarrhea", "constipation") at 1, 3 and 6 months postoperatively based on the respective domains of the validated instrument EORTC QLQ-C30.
Patients visited a clinic dedicated to the post-colectomy "functional and oncologic surveillance" and were asked to answer the HRQoL questionnaires at fi xed postoperative assessment time-points: 1, 3 and 6 months. Completeness of answers to the questionnaires was regularly checked. Only few patients required a family member's assistance due to low educational background and vision problems. Baseline HRQoL scores had already been taken at patients; admission, prior to any treatment.
Th e GIQLI questionnaire consists of 36 questions referring to a specifi c symptom, answered by the patient using fi vepoint Likert scales [3] [4] [5] . Scoring of individual questions is summarized in fi ve categories (emotional function, physical function, social function, symptoms, and treatment reaction). "Global" GIQLI score is calculated by summarizing the points from all 36 questions and its highest score is 144 points. An elevated GIQLI score means a higher quality of life.
Th e EORTC QLQ-C30 consists of 30 questions [4, 6, 7] . All data undergo linear transformation and the scales for severity of symptoms range from 0 (least) to 100 (worst). Th e symptom scales "constipation" (item No 16) and "diarrhea" (item No 17) were used in the current study.
Ethical considerations
Th e study was approved by the ethics committee of Hippocration Hospital, Athens, Greece. Th e purpose of the study was explained clearly to the patients and their informed written consent was obtained. Th e trial was registered at ClinicalTrial.gov of the National Institute of Health with the identifi er number NCT01479907 and assigned name "SYΝBIOTICSCOLON".
Statistical analysis
Continuous data was presented as mean ± standard error of the mean (SEM) and categorical data as percent (%). SPSS statistical soft ware, version 18 (SPSS, Inc., Chicago, IL) was used for all analyses. For numerical data the t-test while for categorical data the chi-square test with the Fisher exact test when appropriate were used. Modelling was performed with linear mixed models which are a variant of generalized linear models permitting fl exibility of modeling not only the means of the data but their variances and covariances as well. Th e longitudinal nature of the data was also adjusted. Estimators were adjusted for confounding variables as described in each test. For numerical data that did not follow the normal distribution non-parametric tests were used (Mann-Whitney, Kosmolgorov-Smirnov). Tests were considered statistically signifi cant if P<0.05. Th e goal for the study was set as a change in the "Global score" of the GIQLI questionnaire between the two groups of at least 10%. Th e calculated sample size was 33 patients per arm giving 80% power. Statistically signifi cant 
Results
No statistically signifi cant diff erences were observed between the two groups regarding age, gender, site of tumor, type of surgery or stage (Table 1) , comorbidities and medications. In general, no bowel motility aff ecting medications were used by any of patients post-operatively and there was no signifi cant diff erence between the two groups regarding the use of narcotics aft er their discharge to home. Th e same standard peri-operative antibiotic chemoprophylaxis appropriate for colorectal resection (2 nd generation cephalosporin and metronidazole fi rst dose pre-operatively and additional doses until the end of the fi rst POD) was delivered to both groups. Inpatient diet was controlled and did not diff er between the groups. Th e percentages of patients subjected to adjuvant treatment were not diff erent between the groups and none of the patients had pre-operative radiotherapy. When the 12 right colectomy specimens of the Synbiotics group patients were compared with the 11 Control group right colectomies, no signifi cant diff erences were observed in terms of the resected terminal ileum length (mean±SEM: 8.5±1.1 vs. 8.2±1.3 cm, P= 0.43) and the amount of large bowel removed (34.8±4.6 vs. 35.7±4.1 cm, P= 0.34).
Likewise, no bowel length diff erences were revealed between the 14 Synbiotics and the 17 Control group sigmoidectomies (24.8±2.6 vs. 27.1±3.1 cm, P=0.18). All low anterior resections for the rectal cancer of the study were restored in a stapled end-to-end fashion at a height of 7.2±1.8 and 6.9±2.1 cm from anal verge at the Synbiotics and Control groups, respectively (P=0. 22) . No statistically signifi cant diff erence was observed between the two groups regarding the baseline GIQLI scores and EORTC QLQ-C30 "diarrhea" and "constipation" domains' scores preoperatively (Table 2) .
GIQLI
Measured GIQLI "Global scores" at the postoperative assessment time-points were better at the Synbiotics than in the Control group [77±1.67 vs. 71.36±1.69, P=0.01 (1 month), 77±1.7 vs. 72.5±1.73, P=0.03 (3 months), 79.23±1.82 vs. 72.75±1.85, P=0.01 (6 months)]. Changes in GIQLI scores through time were examined using linear mixed models with dependent variable the scores over time and covariates the group, age, gender, stage, location, chemotherapy, and procedure. Multivariate linear mixed model analysis showed that synbiotics administration was the only independent statistically signifi cant factor for a substantial amelioration of GIQLI "Global score" (b 5.42, SE (b)1.8, 95% CI 1.78-9.1, P=0.004, Fig. 2A) . Th e assessment time-point was not a signifi cant factor for GIQLI score in the model except for the 6 month-score, which was signifi cantly better than the preoperative one (b 3.69, SE (b)1.58, 95% CI:6.58-0.58, P=0.02). Th e eff ect size of the diff erence expressing the magnitude of this association, measured by Cohen's d, was 0.69 and that was considered as medium to high. Interaction between group and time was also tested in the group but was not found statistically signifi cant.
No statistically signifi cant change occurred between the two groups regarding GIQLI "symptoms" domain over time. Th e change in each group is shown in Fig. 2B . Linear mixed Fig. 2C ). Emotional subdomain scores amongst assessment time-points did not diff er signifi cantly. Females had signifi cantly lower physical function subdomain scores compared to males (b-1.75, SE(b)0.69, 95% CI-3.14--0.37, P=0.013). Finally, the social domain showed a substantial increase in Synbiotics group patients (mean steady contrast between the two groups: 0.72±0.30, P=0.03, Fig. 2D ).
EORTC QLQ-C30
Domains referring to "diarrhea" and "constipation" were isolated. Th e greater the score of the EORTC QLQ-C30 symptoms domains was, the worse the outcome. Th e "diarrhea" score was analyzed by subtracting the score at each time point from the baseline. Each diff erence was then compared between the two groups. Th e equation was ScC30ti-ScC30t0. Th e lower the diff erence was the better the outcome. As shown at Fig. 3 , the mean diff erence in the Synbiotics group remained negative at all time-points. Th erefore, at all time-points the score was always lower than that at baseline, highlighting a postoperative improvement. Th e values reached statistical signifi cance between the two groups when compared at 3 months and 6 months assessment time-points (-13.33±5.45 vs. 4.04±5.6, P=0.04 and -19.1±6.3 vs. 2.01±5.45, P=0.003, respectively). Th e same analysis was used for the "constipation" domain. However, no statistically signifi cant change was observed (data not shown). 
Discussion
In the current randomized study early postoperative synbiotics administration appeared to have a benefi cial eff ect on postcolectomy gastrointestinal function, as that was indicated by the better GIQLI scores at all postoperative assessment time-points, as well as the signifi cant amelioration of the symptom "diarrhea", as assessed by the respective EORTC QLQ-C30 domain. Th e benefi cial action of probiotics supplementation in gastrointestinal disorders has been recognized. Restoration of gut balance, inhibition of the epithelial and mucosal adherence of pathogens, introduction of lower colonic pH favoring the growth of nonpathogenic species, and stimulation of immunity during or aft er antibiotic treatment through receptor competition may be related to the positive gastrointestinal traits and properties of pro-/ synbiotics [26] . In keeping with our results, the use of pro-/ synbiotics to postoperative CRC patients has been reported to be benefi cial in alleviating gastrointestinal symptoms, including diarrhea, the fi rst defecation time, abdominal pain and fl atulence [14, 24, 25] . Probiotics have been associated with a reduction and prevention of non-colectomy-related diarrheas [27, 28] .
In general, early postoperative oral nutrition is regarded as an essential part of fast track recovery aft er colorectal surgery. Food intake can stimulate gastrointestinal peristalsis in the early postoperative period, attenuates catabolism and potentially decreases infectious complications. Synbiotics may play an additional benefi cial role on the context of fast track and enhanced recovery programs aft er colorectal surgery but defi nite suggestions are not currently plausible since no fast track protocols integrating the administration of synbiotics have been tried yet in the clinical practice.
Th e strength of our study lies at the repetitive assessment of patients at fi xed assessment time-points and the use of validated questionnaires to objectify the patients' subjective symptomatology. Only one other group of investigators has utilized a general, non-specifi c HRQoL questionnaire in assessing probiotics eff ects at colectomized patients [22] . Improvements in the functional outcome and/or HRQoL were observed in all groups aft er administration of probiotics, with the right colectomy and proctectomy groups mostly benefi ted [22] .
Diff erent types of colorectal resections were included in our study and this constitutes a potential limitation on deriving defi nitive conclusions on the accurate benefi cial role of synbiotics on specifi c subsets of patients. Another limitation of our study is its complete clinical orientation in regards to outcome measures and the lack of any theoretical explanation that could be provided by associated laboratory or microbial assays. Albeit, it would be more compelling if supporting data regarding actual changes in the bowel microbiota had been included. It has been, though, suffi ciently demonstrated that the use of probiotics aft er surgery has markedly improved intestinal microbial populations [14] [15] [16] . Although local immune function restoration by synbiotics is easily conceivable, improvement infunctional state may not be fully explainable. An explanation could involve immune-mediated neural local and systemic mechanisms [29] . Dendritic cells in the gastrointestinal tract are able to interact with commensal bacteria and the nerves embedded in the gut wall [29] . Th e vagus nerve has an important role in signaling from the gut to the brain and can be stimulated by bacterial products or infl ammatory cytokines [30] . Synbiotics-induced modulation of vagal responses indirectly aff ecting the brain function itself may be speculated. Indeed, in our study, non-gastrointestinal GIQLI domains, such as emotional and social function were improved aft er synbiotics supplementation. Administration of a probiotic formulation has signifi cantly attenuated psychological distress in human volunteers and reduced anxiety-induced behavior in a rat model [31] .
Probiotics may alleviate irritable bowel syndrome (IBS) symptoms [32] . Bowel resections may induce an IBSlike transient gut dysfunction, both due to sensitive and motor disruptions of the visceral nerves, as well as changes in the bacterial ecosystem of the intestine. Implicating pathophysiological mechanisms may be similar. It has been suggested that the generation of nitric oxide (NO), a gas with immuno-modulating but also neuron-modulating properties, by lactobacilli could play an important role [33] . Synbiotics positive eff ects on neuro-motor/sensitive locoregional transmission may be more complex and needs further evaluation. Th e sustained positive eff ects of synbiotics over time in our study may be related to the early "conditioning" of bowel to a better state of function via its repopulation by the "non-pathogenic" microbiota and the restoration of a "better"
Summary Box
What is already known:
• Synbiotics are used as a supportive dietary supplement-based strategy in patients aft er colectomies for cancer • Synbiotics administration has been shown to alleviate gastrointestinal symptoms such as diarrhea, abdominal pain and fl atulence in patients aft er colectomies for colorectal cancer • Improvement in the functional outcome of colectomized patients has been shown only by one group using a non-specifi c HRQoL questionnaire
What the new fi ndings are:
• Early postoperative synbiotics administration improved post-colectomy gastrointestinal function based on better GIQLI scores at all postoperative assessment time-points • Th e early administration of synbiotics in patients aft er colectomy for colorectal cancer led to signifi cant amelioration of "diarrhea" based on the EORTC QLQ-C30 questionnaire mucosa. Nevertheless, these tempting speculations need further confi rmation by additional studies. Despite the tantalizing multitude of trials on the potentially positive role of pre-/pro-/synbiotics, a straightforward translation into a clinical evidence-based strategy remains still unlikely. Incorporation of pre-/pro-/synbiotics formulations in the perioperative management of the CRC patient could be fully supported if further evidence from RCTs with all clinical relevant end-points will be accumulated in the future.
